European Health Catapult | The Innovation Challenge by EIT Health
European Health Catapult lifts the best-of-the-best business concepts from medtech, biotech and digital health across Europe
Join us to boost your innovation!
2019 Applications open soon
European Health Catapult 2018 WINNERS
SyNoesis Therapeutics Ltd. (EIT Health InnoStars): A start-up biotech with the vision to cure Parkinson’s disease (PD) and other major brain diseases has patented a new therapeutic treatment for treating PD.
LIfT BioSciences Ltd. (EIT Health UK-Ireland): Start-up with a vision to develop the world’s first cell bank of “cancer killing neutrophils” for all solid tumours has already shown 40-80% solid tumour necrosis in an FDA approved small study.
Gedea Biotech AB(EIT Health Scandinavia): Develops a safe and antibiotic-free treatment of vaginal infections, affecting most women.
Digital Health category:
Sleepiz (EIT Health Germany): Using wireless signals, their device measures vital signs without touching the patient – enabling non-contact home diagnosis of sleep apnea.
NeuroPsyAI(EIT Health InnoStars): Uses artificial intelligence for earlier identification of signs of neurodegenerative illnesses, such as Alzheimer’s and Parkinson’s disease, in conventional brain scans.
FeetMe(EIT Health France): A connected insole and an associated mobile software that collects and analyses gait spatio-temporal parameters and variability. The innovation is designed to improve mobility outcomes and home rehabilitation through smart active wearable technology.
Aenitis Technologies(EIT Health France): Patented medical devices for continuous, contactless and pressurless sorting of cells in suspensions, to address the challenges of cell therapy units and blood banks in cell sorting, cell washing and on cell isolation for blood, tissues and stem cells processing.
VitaDX International(EIT Health France): Innovative medical device for early bladder cancer diagnosis combines fluorescence imaging and image processing using machine learning algorithms to detect cancerous cells in a urine sample.
HydrUStent, LDA (EIT Health InnoStars): A biodegradable, anti-bacterial and tailor-made stent, with underlying technology protected by a patent, reduces the risk of bacterial infection and the need for surgical procedures, cutting treatment cost by 60%.
Gedea Biotech AB (EIT Health Scandinavia): Develops a safe and antibiotic-free treatment of vaginal infections, affecting most women